Erkrankungen durch hochpathogene Erreger – Teil 1

Aufgrund der weltweit zunehmenden Mobilität gewinnen auch reiseassoziierte Erkrankungen an Bedeutung. Lebensbedrohliche Infektionskrankheiten können schwer kontrollierbare Ausbruchsituationen hervorrufen und stellen somit ein Risiko für das betreuende medizinische Personal, aber auch für die Allgemeinbevölkerung dar. In Teil 1 geht es um hämorrhagische Fiebererkrankungen sowie deren Infektionswege, Symptome und Behandlung.

• Literatur

• 1 United Nations World Tourism Organization (UNWTO). Statistics. Zugriff am 09. September 2022 unter: www.unwto.org/statistics
• 2 Wendt S, Beier D, Paquet D. et al. Medical Advice for Travelers. Dtsch Arztebl Int 2021; 118: 349-356
• 3 Paquet D, Jung L, Trawinski H. et al. Fever in the Returning Traveler. Dtsch Arztebl Int 2022; 119: 400-407
• 4 UK Health Security Agency. High consequence infectious diseases (HCID) – Guidance and information about high consequence infectious diseases and their management in England. Zugriff am 09. September 2022 unter: www.gov.uk/guidance/high-consequence-infectious-diseases-hcid
• 5 Reuter S, Jensen BO, Häussinger D. Infektionsschutz bei Infektionskrankheiten durch hochpathogene Erreger. Krankenhaushygiene up2date 2011; 6: 285-297
• 6 Verordnung über Sicherheit und Gesundheitsschutz bei Tätigkeiten mit Biologischen Arbeitsstoffen. Zugriff am 09. September 2022 unter: www.gesetze-im-internet.de/biostoffv_2013%20
• 7 Robert Koch-Institut (RKI). Rahmenkonzept Ebolafieber. Zugriff am 09. September 2022 unter: www.rki.de/DE/Content/InfAZ/E/Ebola/Rahmenkonzept_Ebola.pdf
• 8 Chertow DS, Kleine C, Edwards JK. et al. Ebola virus disease in West Africa – clinical manifestations and management. N Engl J Med 2014; 371: 2054-2057
• 9 Garske T, Cori A, Ariyarajah A. et al. Heterogeneities in the case fatality ratio in the West African Ebola outbreak 2013–2016. Philos Trans R Soc Lond B Biol Sci 2017; 372: 20160308
• 10 Uyeki TM, Mehta AK, Davey Jr RT. et al. Clinical Management of Ebola Virus Disease in the United States and Europe. N Engl J Med 2016; 374: 636-646
• 11 Prescott J, Bushmaker T, Fischer R. et al. Postmortem stability of Ebola virus. Emerg Infect Dis 2015; 21: 856-859
• 12 Deen GF, Broutet N, Xu W. et al. Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors – Final Report. N Engl J Med 2017; 377: 1428-1437
• 13 Robert Koch-Institut (RKI). Antworten auf häufig gestellte Fragen zu Ebolafieber. Zugriff am 09. September 2022 unter: www.rki.de/SharedDocs/FAQ/Ebola/Ebola.html
• 14 Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4: 487-498
• 15 World Health Organization (WHO). Marburg Virus Disease. www.who.int/health-topics/marburg-virus-disease#tab=tab_1
• 16 Timen A, Koopmans MP, Vossen AC. et al. Response to imported case of Marburg hemorrhagic fever, the Netherlands. Emerg Infect Dis 2009; 15: 1171-1175
• 17 Centers for Disease Control and Prevention (CDC). Imported case of Marburg hemorrhagic fever – Colorado, 2008. MMWR Morb Mortal Wkly Rep 2009; 58: 1377-1381
• 18 Dulin N, Spanier A, Merinio K. et al. Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials. Vaccine 2021; 39: 202-208
• 19 Spencer RC, Lightfoot NF. Preparedness and Response to Bioterrorism. J Infect 2001; 43: 104-110
• 20 Agbonlahor DE, Erah E, Agba IM. et al. Prevalence of Lassa virus among rodents trapped in three South-South States of Nigeria. J Vector Borne Dis 2017; 54: 146-150
• 21 Robert Koch-Institut (RKI). Ratgeber Lassafieber. Zugriff am 09. September 2022 unter: www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Lassa-Fieber.html;jsessionid=30E50BD21C978704F510E602BB55A14D.internet122?nn=2386228%20
• 22 Forni D, Pontremoli C, Pozzoli U. et al. Ancient evolution of mammarenaviruses: adaption via changes in the L protein and no evidence for host-virus codivergence. Genome Biol Evol 2018; 10: 863-874
• 23 Fichet-Calvet E, Rogers DJ. Risk Maps of Lassa Fever in West Africa. PLoS Negl Trop Dis 2009; 3: e388
• 24 Frame JD, Baldwin Jr, Gocke DJ. et al. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg 1970; 19: 670-676
• 25 Centers for Disease Control and Prevention (CDC). Lassa Fever. Zugriff am 09. September 2022 unter: www.cdc.gov/vhf/lassa/index.html
• 26 Ibukun FI. Inter-Lineage variation of Lassa virus glycoprotein epitopes: a challenge to Lassa virus vaccine development. Viruses 2020; 12: 386
• 27 Murphy HL, Ly H. Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments. Virulence 2021; 12: 2989-3014
• 28 Fisher-Hoch SP, Tomori O, Nasisi A. et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 1995; 311: 857-859
• 29 UK Health Security Agency. Lassa fever: origins, reservoirs, transmission and guidelines. Zugriff am 09. September 2022 unter: www.gov.uk/guidance/lassa-fever-origins-reservoirs-transmission-and-guidelines#symptoms
• 30 Johnson KM, McCormick JB, Webb PA. et al. Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 1987; 155: 456-464
• 31 McCormick JB, King IJ, Webb PA. et al. Lassa Fever. New Engl J Med 1986; 314: 20-26
• 32 Mateer EJ, Huang C, Shehu NY. et al. Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden. PLoS Negl Trop Dis 2018; 12: e0006187
• 33 Salam AP, Duvignaud A, Jaspard M. et al. Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing. PLoS Negl Trop Dis 2022; 16: e0010289
• 34 Raabe VN, Kann G, Ribner BS. et al. Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. Clin Infect Dis 2017; 65: 855-859
• 35 Fischer RJ, Purushotham JN, van Doremalen N. et al. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. NPJ Vaccines 2021; 6: 32
• 36 European Centre for Disease Prevention and Control (ECDC). Factsheet about Crimean-Congo haemorrhagic fever. Zugriff am 09. September 2022 unter: www.ecdc.europa.eu/en/crimean-congo-haemorrhagic-fever/facts/factsheet
• 37 Sidira P, Maltezou HC, Haidich AB. et al. Seroepidemiological study of Crimean‐Congo haemorrhagic fever in Greece, 2009–2010. Clin Microbiol Infect 2012; 18: E16-E19
• 38 Arellano ER de, Hernández L, Goyanes MJ. et al. Phylogenetic Characterization of Crimean-Congo Hemorrhagic Fever Virus, Spain. Emerg Infect Dis 2017; 23: 2078-2080
• 39 Portillo A, Palomar AM, Santibáñez P. et al. Epidemiological Aspects of Crimean-Congo Hemorrhagic Fever in Western Europe: What about the Future?. Microorg 2021; 9: 649
• 40 Ölschläger S, Gabriel M, Schmidt-Chanasit J. et al. Complete sequence and phylogenetic characterisation of Crimean–Congo hemorrhagic fever virus from Afghanistan. J Clin Virol 2011; 50: 90-92
• 41 World Health Organization (WHO). Prioritizing diseases for research and development in emergency contexts. Zugriff am 09. September 2022 unter: www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts
• 42 Ergonul O, Celikbas A, Yildirim U. et al. Pregnancy and Crimean‐Congo haemorrhagic fever. Clin Microbiol Infect 2010; 16: 647-650
• 43 Leblebicioglu H, Sunbul M, Guner R. et al. Healthcare-associated Crimean-Congo haemorrhagic fever in Turkey, 2002–2014: a multicentre retrospective cross-sectional study. Clin Microbiol Infect 2016; 22: 387.e1-387.e4
• 44 Akinci E, Bodur H, Sunbul M. et al. Prognostic factors, pathophysiology and novel biomarkers in Crimean-Congo hemorrhagic fever. Antivir Res 2016; 132: 233-243
• 45 Oestereich L, Rieger T, Neumann M. et al. Evaluation of Antiviral Efficacy of Ribavirin, Arbidol, and T-705 (Favipiravir) in a Mouse Model for Crimean-Congo Hemorrhagic Fever. PLoS Neglect Trop D 2014; 8: e2804
• 46 Appelberg S, John L, Pardi N. et al. Nucleoside-Modified mRNA Vaccines Protect IFNAR–/– Mice against Crimean-Congo Hemorrhagic Fever Virus Infection. J Virol 2021; 96: e01568-21
• 47 Defense Against Biological Attacks, Volume I. Singh SK, Kuhn JH. 1. Aufl. Heidelberg: Springer; 2019